Smith W Bradford
Transaction: 05/14/2026
SELL
Change
-640
Price
Not reported
Filing
05/15/2026
Type
SELL
Lyra Therapeutics, Inc.
LYRA • Biotechnology
$0.20
— 0.00 (0.00%)
Current price
EarningsLatest report: Dec 31, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$3.11M
Growth
-25.4%
Cash Flow
0/5
Trend
Negative
Evidence
Healthy liquidity · 1.71Weak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Mar 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.20
Change0.00%
Shares Out15.53M
Market Cap$3.11M
Enterprise Value$17.47M
Beta0.69
P/E-0.11
P/S7.81
P/B-0.29
P/FCF-0.11
EV/Sales43.90
EV/EBITDA-0.63
Price$0.20
Change0.00%
Shares Out15.53M
Market Cap$3.11M
Enterprise Value$17.47M
Beta0.69
P/E-0.11
P/S7.81
P/B-0.29
P/FCF-0.11
EV/Sales43.90
EV/EBITDA-0.63
EV/FCF-0.60
Earnings Yield-930.79%
FCF Yield-932.59%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-77.94%
Profit Margin-72.66%
Debt/Eq-2.82
Current Ratio1.71
Quick Ratio1.71
Revenue 5Y-25.36%
Target$0.50
Target Upside150.00%
Target Median$0.50
Target Range0.50 - 0.50
Volume77.92K
Avg Volume106.35K
EPS Surprise10.59
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
67/100
Growth Potential
Revenue and expansion
59/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Healthy liquidity · 1.71Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
70/100
Bullish
Bullish
2
Hold
3
Bearish
0
Price Target
2026-06-06
Low
$0.50
Mean
$0.50
Median
$0.50
High
$0.50
Insider Transactions
Recent executive and insider activity
Cavalier Jason
Transaction: 04/01/2026
SELL
Change
-667
Price
Not reported
Filing
04/03/2026
Type
SELL
Palasis Maria
Transaction: 04/01/2026
SELL
Change
-2,000
Price
Not reported
Filing
04/03/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Smith W Bradford | SELL | -640 | Not reported | 05/14/2026 | 05/15/2026 |
| Cavalier Jason | SELL | -667 | Not reported | 04/01/2026 | 04/03/2026 |
| Palasis Maria | SELL | -2,000 | Not reported | 04/01/2026 | 04/03/2026 |
| Palasis Maria | SELL | -1,702 | $3.36 | 01/06/2026 | 01/08/2026 |
| Cavalier Jason | SELL | -769 | $3.36 | 01/06/2026 | 01/08/2026 |
| PERCEPTIVE ADVISORS LLC | SELL | -3,213 | $3.90 | 11/13/2025 | 11/13/2025 |
| PERCEPTIVE ADVISORS LLC | SELL | -883 | $4.06 | 11/12/2025 | 11/13/2025 |
| PERCEPTIVE ADVISORS LLC | SELL | -537 | $4.31 | 11/11/2025 | 11/13/2025 |
| PERCEPTIVE ADVISORS LLC | SELL | -1,869 | $4.54 | 11/10/2025 | 11/10/2025 |
| PERCEPTIVE ADVISORS LLC | SELL | -1,993 | $4.75 | 11/07/2025 | 11/10/2025 |
| PERCEPTIVE ADVISORS LLC | SELL | -3,247 | $5.18 | 11/06/2025 | 11/10/2025 |
| Palasis Maria | OTHER | 0 | Not reported | 10/01/2025 | 10/08/2025 |
| Palasis Maria | BUY | +3,667 | $303.50 | 10/01/2025 | 10/03/2025 |
| Cavalier Jason | SELL | -684 | $8.91 | 07/10/2025 | 07/14/2025 |
| Palasis Maria | SELL | -1,565 | $8.91 | 07/10/2025 | 07/14/2025 |
| Smith W Bradford | BUY | +32,000 | Not reported | 05/14/2025 | 05/16/2025 |
| snyderman nancy lynn MD | BUY | +32,000 | Not reported | 05/14/2025 | 05/16/2025 |
| TOBIN JAMES R | BUY | +32,000 | Not reported | 05/14/2025 | 05/16/2025 |
| MERRIFIELD C ANN | BUY | +32,000 | Not reported | 05/14/2025 | 05/16/2025 |
| Cavalier Jason | BUY | +420,000 | Not reported | 01/08/2025 | 01/10/2025 |